Chemours Co SEC Filings

Chemours Co Chief Executive Officer Denise Dignam received 2,261 shares of common stock as a performance-based stock award tied to 2023 compensation, issued at no cash cost to her after performance conditions were certified. To cover taxes on vesting, 742 shares were automatically withheld at $18.4100 per share, and the footnotes state that no shares were sold. Following these transactions and an adjustment for a prior administrative error, her directly owned and related holdings total 187,995.8721 shares, including restricted stock units and dividend equivalent units.

The Chemours Company filed a Form 8-K to report a private debt financing. The company launched and priced an upsized offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034, increased from a previously announced $600,000,000 offering size.

The notes mature on March 15, 2034 and will pay interest semi-annually on March 15 and September 15, starting September 15, 2026. Chemours intends to use the net proceeds to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its outstanding 5.750% senior notes due 2028. The notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.

The Chemours Company filed a Form 8-K to report a private debt financing. The company launched and priced an upsized offering of $700,000,000 aggregate principal amount of 7.875% senior unsecured notes due 2034, increased from a previously announced $600,000,000 offering size.

The notes mature on March 15, 2034 and will pay interest semi-annually on March 15 and September 15, starting September 15, 2026. Chemours intends to use the net proceeds to redeem its outstanding 5.375% senior notes due 2027 and partially redeem its outstanding 5.750% senior notes due 2028. The notes are being sold in a private offering to qualified institutional buyers under Rule 144A and to certain non-U.S. investors under Regulation S.

The Chemours Company provides a detailed annual overview of its business, strategy, and key risks. The company operates three main segments: Thermal & Specialized Solutions (refrigerants and thermal management), Titanium Technologies (TiO₂ pigments), and Advanced Performance Materials (high‑end fluoropolymers and specialty materials).

Chemours’ “Pathway to Thrive” strategy focuses on operational excellence, targeted growth in areas like data center cooling, next‑generation refrigerants, and semiconductors, active portfolio management, and addressing legacy litigation and environmental matters. A major Titanium Technologies transformation included shutting its Kuan Yin, Taiwan TiO₂ plant, generating cost savings and leading to land sale agreements of about $360 million, with proceeds intended to reduce debt.

The company emphasizes sustainability, targeting a 60% reduction in Scope 1 and 2 greenhouse gas emissions and a 25% reduction in Scope 3 intensity by 2030, with a long‑term goal of net zero by 2050. It highlights significant environmental, regulatory, PFAS‑related, and litigation exposures, as well as dependence on global economic conditions, raw material costs, and robust safety and human‑capital management for long‑term performance.

The Chemours Company reported fourth quarter 2025 net sales of $1.3 billion, down 2% year over year, and a net loss of $47 million, or $0.31 per diluted share. Adjusted EBITDA was $128 million versus $168 million a year earlier.

For full year 2025, net sales were $5.8 billion, essentially flat, but results swung to a net loss of $386 million, or $2.57 per share, from net income of $69 million, largely due to litigation-related and environmental charges. Adjusted EBITDA slipped modestly to $742 million from $768 million. TSS delivered record net sales of $2.1 billion and Adjusted EBITDA of $670 million, while TT and APM saw sharp profit declines. Net debt was $3.5 billion with a 4.7x net leverage ratio. For 2026, Chemours guides to 3–5% net sales growth, Adjusted EBITDA of $800–$900 million, and Free Cash Flow Conversion above 25%.

Chemours Co officer Michael Robert Foley filed an initial statement of beneficial ownership as of February 4, 2026. He reported holding 3,500 shares of Chemours common stock in direct ownership. Foley is identified with the title President, Titanium Technologies, and no derivative securities were listed.

The Chemours Company agreed to sell ten parcels of land in Kuan Yin, Taiwan, for a total purchase price of approximately $360 million. The sale is being executed through four real estate sale and purchase agreements between a Chemours subsidiary and four affiliated buyers, and the company plans to use the cash proceeds to reduce its debt obligations.

The transaction is expected to close in one or more stages by mid-year 2026, subject to closing conditions and local regulatory approvals, including environmental conditions. The agreements include customary representations, warranties, covenants, indemnities, and termination provisions for industrial property deals, and were negotiated on an arm’s-length basis with no other material relationships between Chemours and the buyers. Chemours also issued a press release outlining the property sale.

Chemours Co director reports new deferred stock units. A member of the board received 1,298 deferred stock units on 12/31/2025. Each unit is the economic equivalent of one share of Chemours common stock at a reference price of $11.79. These deferred stock units, together with related dividend equivalent units, will be paid in the second calendar year after the director’s service on the board ends. Following this grant, the director beneficially owns 4,615.309 derivative securities in the form of deferred stock units, held directly.

Chemours Company director reports deferred stock units grant

A director of Chemours Company reported receiving 2,226 deferred stock units on 12/31/2025. Each deferred stock unit is the economic equivalent of one share of Chemours common stock and becomes payable in the first month after the director’s termination of service. The transaction price is listed as $11.79 per unit. Following this grant, the reporting person beneficially owns a total of 6,216.3946 deferred stock units, which include both deferred stock units and related dividend equivalent units, all held in direct ownership.

Chemours (CC) reported Q3 2025 results with net sales of $1,495 million versus $1,508 million a year ago. The company returned to profitability with net income of $60 million, or $0.40 per diluted share, compared to a net loss of $32 million in Q3 2024. Gross profit was $233 million, and selling, general and administrative expense declined to $109 million.

For the first nine months, net sales were $4,478 million and net loss was $(325) million ($(2.16) per share). Operating cash flow improved to $127 million year-to-date, versus $(771) million in the prior-year period. As of September 30, 2025, cash and cash equivalents were $613 million, with $953 million available under the revolving credit facility and current liabilities of $1,880 million. Total equity was $300 million. The company recorded a quarterly dividend of $0.0875 per share. Management revised prior periods for immaterial errors, reducing 2024 year-to-date net income by $13 million.

The Chemours Company furnished an update on its business by providing a press release and prepared remarks covering Q3 2025 financial results. The materials are included as Exhibits 99.1 and 99.2 and are designated as “furnished,” not “filed,” under the Exchange Act.

The company plans to post an investor presentation and the prepared remarks to its investor relations website by 8:00 a.m. Eastern Daylight Time on Friday, November 7, 2025, aligned with its scheduled conference call.